UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 24, 2022, The Joint Corp. (the “Company”) issued a press release announcing its preliminary financial results for the fourth quarter and full year ended December 31, 2021. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The Company is posting an earnings presentation to its website at https://ir.thejoint.com/. A copy of the earnings presentation is being furnished herewith as Exhibit 99.2. The Company will use the earnings presentation during its earnings conference call on February 24, 2022 and also may use the earnings presentation from time to time in conversations with analysts, investors and others.
The information furnished in this Item 7.01 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The information contained in Exhibit 99.2 is summary information that is intended to be considered in the context of the Company’s filings with the SEC. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
(d) Exhibits
Exhibit Number | Description | |||
99.1 | Press Release dated February 24, 2022 | |||
99.2 | The Joint Corp. Earnings Presentation, February 2022 | |||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
The Joint Corp. | ||
Date: February 24, 2022 | By: | /s/ Peter D. Holt |
Peter D. Holt | ||
President and Chief Executive Officer | ||
EXHIBIT 99.1
The Joint Corp. Reports Preliminary Fourth Quarter and Year-end 2021 Financial Results
- Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 -
- Sold 156 Franchise Licenses, Compared to 121 in 2020 -
- Opened 130 Clinics, Including 20 Greenfields, Bringing the Total Corporate Count to 96 at Year End -
SCOTTSDALE, Ariz., Feb. 24, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its preliminary financial results for the quarter and year ended December 31, 2021.
Financial Highlights: Preliminary Q4 2021 Compared to Q4 2020
Financial Highlights: Preliminary 2021 Compared to 2020
2021 Full Year Operating Highlights
“During 2021, The Joint demonstrated remarkable resilience to pandemic pressures, continued to accelerate momentum, and delivered record openings, new patients, revenue, and Adjusted EBITDA,” said Peter D. Holt, President and Chief Executive Officer of The Joint Corp. “As the market continues to expand, we continue to fuel our growth, as illustrated by our increasing number of patients, franchisees, clinics, and franchise license sales. In 2022, we are focusing efforts on three key enterprise growth initiatives: forging the chiropractic dream, by offering the best career path for chiropractic doctors; harnessing the power of our data, by leveraging our new CRM platform; and accelerating the pace of clinic growth, through a continuous improvement in our comprehensive franchise sales and clinic opening strategy. We ended 2021 with 706 clinics and are well positioned to achieve our goal of 1,000 clinics in operation by the end of 2023, creating the foundation for continued future growth.”
____________________________________
1 System-wide sales include sales at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.
2 Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
Quarterly Financial Results: Preliminary Unaudited Fourth Quarter 2021 Vs. Fourth Quarter 2020
Revenue was $22.4 million in the fourth quarter of 2021, compared to $17.0 million in the fourth quarter of 2020. The increase reflects a greater number of franchised and corporate clinics and continued organic growth. Cost of revenue was $2.4 million, compared to $1.9 million in the fourth quarter of 2020, reflecting the associated higher regional developer royalties and commissions, the increase in franchised clinics, and the higher website hosting costs related to the new IT platform, which went live in July 2021.
Selling and marketing expenses were $2.9 million, up 38%, driven by the larger number of franchised and company-owned or managed clinics, the grand opening expenses for 9 greenfields, and the timing of the national marketing fund spend as well as the new brand campaign.
Depreciation and amortization expenses increased for the fourth quarter of 2021, as compared to the prior year period, primarily due to the amortization of development rights reacquired in December 2020 and January 2021, the amortization of intangibles related to the 2021 clinic acquisitions, and the depreciation expenses associated with the new IT platform and greenfield development.
General and administrative expenses were $14.6 million, compared to $9.5 million in the fourth quarter of 2020. The increase was primarily driven by an increase in company-owned or managed clinic expenses, an increase in payroll to remain competitive in the tight labor market, professional fees, and IT expenses to support continued clinic count and revenue growth.
Operating income was $663,000, including the impact of the accelerated greenfield development and depreciation and amortization from reacquired development rights. This compares to $2.8 million in the fourth quarter of 2020. Income tax expense was $424,000, compared to a benefit of $7.9 million in the fourth quarter of 2020, which included the reversal of the tax valuation allowance of $8.9 million. Net income was $224,000, or $0.01 per diluted share, compared to $10.6 million, or $0.72 per diluted share, in the fourth quarter of 2020.
Adjusted EBITDA was $2.7 million, compared to $3.7 million in the fourth quarter of 2020. The company defines Adjusted EBITDA, a non-GAAP measure, as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income before net interest, tax expense, depreciation, and amortization expenses.
Full Year Financial Results: Preliminary 2021 Vs. 2020
Revenue was $81.2 million for 2021, compared to $58.7 million in 2020. Operating income and net income were $6.0 million and $7.2 million, compared to $5.5 million and $13.2 million in 2020, respectively. Adjusted EBITDA was $13.3 million, compared to $9.1 million in 2020.
These fourth quarter and full year 2021 results are preliminary, unaudited, and subject to adjustments. As a result of the foregoing, certain information provided herein is subject to change.
Balance Sheet Liquidity
Unrestricted cash was $19.5 million at December 31, 2021, compared to $20.6 million at December 31, 2020. The change reflects net cash provided by operating activities of $15.2 million offset by $14.1 million of investing activities consisting of acquisitions, greenfield developments, and IT capital expenditures, as well as the $2.0 million of net cash used in financing activities primarily driven by the repayment of the Paycheck Protection Program loan in March 2021.
2022 Guidance
Management provided 2022 guidance for revenue, Adjusted EBITDA, and clinic openings.
Conference Call
The Joint Corp. management will host a conference call at 5 p.m. ET on Thursday, February 24, 2022, to discuss the fourth quarter and year-end 2021 financial result. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 765-507-2604 or 844-464-3931 and referencing code 3285473 approximately 15 minutes prior to the start time.
The accompanying slide presentation will be in the IR section of the website under Presentations and in Events. A live webcast of the conference call will also be available on the IR section of the company’s website at https://ir.thejoint.com/events. An audio replay will be available two hours after the conclusion of the call through March 3, 2022. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 3285473.
Non-GAAP Financial Information
This release includes a presentation of non-GAAP financial measures. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Reconciliation of net income/(loss) to EBITDA and Adjusted EBITDA is presented in a table below. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income before net interest, tax expense, depreciation, and amortization expenses.
EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company’s financial statements filed with the SEC.
Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, short-selling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, our failure to remediate the current or future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence, and other factors described in our filings with the SEC, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 to be filed with the SEC and subsequently-filed current and quarterly reports. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
Management will be disclosing in our Form 10-K that our management concluded that our internal controls over financial reporting were not effective as of December 31, 2021, and we expect our auditors to express an adverse opinion on the Company’s internal control over financial reporting as of December 31, 2021, due to a material weakness. The details of this material weakness will be provided in our upcoming 10-K filing. We have undertaken remediation measures to address the material weakness, which we expect will be completed prior to the end of fiscal year 2022.
About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, the company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With more than 600 locations nationwide and over eight million patient visits annually, The Joint is a key leader in the chiropractic industry. Named on Franchise Times “Top 200+ Franchises” and Entrepreneur’s “Franchise 500®” lists, The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.
Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.
Media Contact: Margie Wojciechowski, The Joint Corp., margie.wojciechowski@thejoint.com
Investor Contact: Kirsten Chapman, LHA Investor Relations, 415-433-3777, thejoint@lhai.com
– Financial Tables Follow –
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES PRELIMINARY CONSOLIDATED BALANCE SHEETS (unaudited) | |||||||
December 31, 2021 | December 31, 2020 | ||||||
ASSETS | (as revised) | ||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 19,526,119 | $ | 20,554,258 | |||
Restricted cash | 386,219 | 265,371 | |||||
Accounts receivable, net | 3,391,120 | 1,850,499 | |||||
Deferred franchise and regional development costs, current portion | 994,587 | 897,551 | |||||
Prepaid expenses and other current assets | 2,283,285 | 1,566,025 | |||||
Total current assets | 26,581,330 | 25,133,704 | |||||
Property and equipment, net | 14,388,946 | 8,747,369 | |||||
Operating lease right-of-use asset | 17,247,928 | 11,581,435 | |||||
Deferred franchise and regional development costs, net of current portion | 5,505,420 | 4,340,756 | |||||
Intangible assets, net | 5,403,390 | 2,865,006 | |||||
Goodwill | 5,085,203 | 4,625,604 | |||||
Deferred tax assets | 9,261,191 | 8,088,073 | |||||
Deposits and other assets | 567,202 | 431,336 | |||||
Total assets | $ | 84,040,610 | $ | 65,813,283 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,705,568 | $ | 1,561,648 | |||
Accrued expenses | 1,444,837 | 770,221 | |||||
Co-op funds liability | 386,219 | 248,468 | |||||
Payroll liabilities | 3,906,317 | 2,776,036 | |||||
Debt under the Credit Agreement | 2,000,000 | — | |||||
Operating lease liability, current portion | 4,218,635 | 2,918,140 | |||||
Finance lease liability, current portion | 49,855 | 70,507 | |||||
Deferred franchise and regional development fee revenue, current portion | 3,191,892 | 3,000,369 | |||||
Deferred revenue from company clinics ($3.5 million and $2.8 million attributable to VIEs as of December 31, 2021 and 2020) | 5,367,250 | 4,201,548 | |||||
Debt under the Paycheck Protection Program | — | 2,727,970 | |||||
Other current liabilities | 539,499 | 707,085 | |||||
Total current liabilities | 22,810,072 | 18,981,992 | |||||
Operating lease liability, net of current portion | 16,094,361 | 10,632,672 | |||||
Finance lease liability, net of current portion | 87,939 | 132,469 | |||||
Debt under the Credit Agreement | — | 2,000,000 | |||||
Deferred franchise and regional development fee revenue, net of current portion | 15,458,921 | 13,503,745 | |||||
Other liabilities | 27,231 | 27,230 | |||||
Total liabilities | 54,478,524 | 45,278,108 | |||||
Stockholders' equity: | |||||||
Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of December 31, 2021 and 2020 | — | — | |||||
Common stock, $0.001 par value; 20,000,000 shares authorized, 14,451,355 shares issued and 14,419,712 shares outstanding as of December 31, 2021 and 14,174,237 shares issued and 14,157,070 outstanding as of December 31, 2020 | 14,450 | 14,174 | |||||
Additional paid-in capital | 43,925,057 | 41,350,001 | |||||
Treasury stock 31,643 shares as of December 31, 2021 and 17,167 shares as of December 31, 2020, at cost | (850,838 | ) | (143,111 | ) | |||
Accumulated deficit | (13,551,583 | ) | (20,685,989 | ) | |||
Total The Joint Corp. stockholders' equity | 29,537,086 | 20,535,075 | |||||
Non-controlling Interest | 25,000 | 100 | |||||
Total equity | 29,562,086 | 20,535,175 | |||||
Total liabilities and stockholders' equity | $ | 84,040,610 | $ | 65,813,283 | |||
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES PRELIMINARY CONSOLIDATED INCOME STATEMENTS (unaudited) | |||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||
Revenues: | |||||||||||||||
Revenues from company-owned or managed clinics | $ | 12,214,405 | $ | 9,216,342 | $ | 44,741,722 | $ | 31,771,288 | |||||||
Royalty fees | 6,246,489 | 4,728,476 | 22,062,989 | 15,886,051 | |||||||||||
Franchise fees | 691,418 | 544,954 | 2,659,098 | 2,100,800 | |||||||||||
Advertising fund revenue | 1,777,582 | 1,330,333 | 6,298,923 | 4,506,413 | |||||||||||
Software fees | 899,345 | 729,552 | 3,286,888 | 2,694,520 | |||||||||||
Regional developer fees | 206,598 | 232,830 | 848,640 | 876,804 | |||||||||||
Other revenues | 397,761 | 255,657 | 1,293,721 | 847,100 | |||||||||||
Total revenues | 22,433,598 | 17,038,144 | 81,191,981 | 58,682,976 | |||||||||||
Cost of revenues: | |||||||||||||||
Franchise and regional developer cost of revenues | 2,088,847 | 1,808,814 | 7,408,125 | 6,090,203 | |||||||||||
IT cost of revenues | 320,954 | 132,612 | 1,105,652 | 417,265 | |||||||||||
Total cost of revenues | 2,409,801 | 1,941,426 | 8,513,777 | 6,507,468 | |||||||||||
Selling and marketing expenses | 2,920,798 | 2,119,864 | 11,424,416 | 7,804,420 | |||||||||||
Depreciation and amortization | 1,813,807 | 672,525 | 6,088,947 | 2,734,462 | |||||||||||
General and administrative expenses | 14,611,112 | 9,527,397 | 49,124,490 | 36,195,817 | |||||||||||
Total selling, general and administrative expenses | 19,345,717 | 12,319,786 | 66,637,853 | 46,734,699 | |||||||||||
Net loss (gain) on disposition or impairment | 14,868 | 2,092 | 31,835 | (51,321 | ) | ||||||||||
Income from operations | 663,212 | 2,774,840 | 6,008,516 | 5,492,130 | |||||||||||
Other expense, net | (15,829 | ) | (24,230 | ) | (69,878 | ) | (79,478 | ) | |||||||
Income before income tax expense (benefit) | 647,383 | 2,750,610 | 5,938,638 | 5,412,652 | |||||||||||
Income tax expense (benefit) | 423,827 | (7,882,213 | ) | (1,220,669 | ) | (7,754,662 | ) | ||||||||
Net income | $ | 223,556 | $ | 10,632,823 | $ | 7,159,307 | $ | 13,167,314 | |||||||
Earnings per share: | |||||||||||||||
Basic earnings per share | $ | 0.02 | $ | 0.75 | $ | 0.50 | $ | 0.94 | |||||||
Diluted earnings per share | $ | 0.01 | $ | 0.72 | $ | 0.48 | $ | 0.90 | |||||||
Basic weighted average shares | 14,416,273 | 14,108,164 | 14,319,448 | 14,003,708 | |||||||||||
Diluted weighted average shares | 14,946,865 | 14,716,658 | 14,935,577 | 14,582,877 | |||||||||||
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES PRELIMINARY CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) | |||||||
Year Ended December 31, | |||||||
2021 | 2020 | ||||||
Cash flows from operating activities: | |||||||
Net income | $ | 7,159,307 | $ | 13,167,314 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Depreciation and amortization | 6,088,947 | 2,734,462 | |||||
Net loss on disposition or impairment (non-cash portion) | 125,237 | 1,193 | |||||
Net franchise fees recognized upon termination of franchise agreements | (133,007 | ) | (57,080 | ) | |||
Deferred income taxes | (1,173,118 | ) | (8,097,494 | ) | |||
Stock based compensation expense | 1,056,015 | 885,975 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | (1,540,621 | ) | 794,586 | ||||
Prepaid expenses and other current assets | (717,260 | ) | (443,547 | ) | |||
Deferred franchise costs | (1,418,235 | ) | (899,056 | ) | |||
Deposits and other assets | (148,516 | ) | (43,380 | ) | |||
Accounts payable | (14,373 | ) | (90,429 | ) | |||
Accrued expenses | 522,115 | 389,973 | |||||
Payroll liabilities | 1,130,281 | (68,071 | ) | ||||
Deferred revenue | 3,231,456 | 2,206,063 | |||||
Other liabilities | 1,064,552 | 702,733 | |||||
Net cash provided by operating activities | 15,232,780 | 11,183,242 | |||||
Cash flows from investing activities: | |||||||
Acquisition of AZ clinics | (1,925,000 | ) | (534,000 | ) | |||
Acquisition of NC clinics | (3,840,135 | ) | — | ||||
Purchase of property and equipment | (6,989,534 | ) | (3,156,233 | ) | |||
Reacquisition and termination of regional developer rights | (1,388,700 | ) | (1,039,500 | ) | |||
Payments received on notes receivable | — | 128,724 | |||||
Net cash used in investing activities | (14,143,369 | ) | (4,601,009 | ) | |||
Cash flows from financing activities: | |||||||
Payments of finance lease obligation | (80,322 | ) | (57,097 | ) | |||
Purchases of treasury stock under employee stock plans | (707,727 | ) | (32,070 | ) | |||
Proceeds from exercise of stock options | 1,519,317 | 1,009,364 | |||||
Proceeds from the Credit Agreement, net of related fees | — | 1,947,352 | |||||
Proceeds from the Paycheck Protection Program | — | 2,727,970 | |||||
Repayment of debt under the Paycheck Protection Program | (2,727,970 | ) | — | ||||
Net cash (used in) provided by financing activities | (1,996,702 | ) | 5,595,519 | ||||
(Decrease) increase in cash | (907,291 | ) | 12,177,752 | ||||
Cash and restricted cash, beginning of period | 20,819,629 | 8,641,877 | |||||
Cash and restricted cash, end of period | $ | 19,912,338 | $ | 20,819,629 | |||
December 31, 2021 | December 31, 2020 | ||||||
Reconciliation of cash, cash equivalents and restricted cash: | |||||||
Cash and cash equivalents | $ | 19,526,119 | $ | 20,554,258 | |||
Restricted cash | 386,219 | 265,371 | |||||
$ | 19,912,338 | $ | 20,819,629 | ||||
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES PRELIMINARY RECONCILIATION FOR GAAP TO NON-GAAP (unaudited) | |||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
Non-GAAP Financial Data: | 2021 | 2020 | 2021 | 2020 | |||||||||||
Net income | $ | 223,556 | $ | 10,632,823 | $ | 7,159,307 | $ | 13,167,314 | |||||||
Net interest | 15,829 | 24,230 | 69,878 | 79,478 | |||||||||||
Depreciation and amortization expense | 1,813,807 | 672,525 | 6,088,947 | 2,734,462 | |||||||||||
Income tax expense (benefit) | 423,827 | (7,882,213 | ) | (1,220,669 | ) | (7,754,662 | ) | ||||||||
EBITDA | $ | 2,477,019 | $ | 3,447,365 | $ | 12,097,463 | $ | 8,226,592 | |||||||
Stock compensation expense | 229,107 | 207,269 | 1,056,015 | 885,975 | |||||||||||
Acquisition related expenses | 20,370 | 41,716 | 68,716 | 41,716 | |||||||||||
Net loss (gain) on disposition or impairment | 14,868 | 2,092 | 31,835 | (51,321 | ) | ||||||||||
Adjusted EBITDA | $ | 2,741,364 | $ | 3,698,442 | $ | 13,254,029 | $ | 9,102,962 | |||||||
EXHIBIT 99.2
© 2022 The Joint Corp. All Rights Reserved. 1 Q4 2021 Preliminary Financial Results As of December 31, 2021 | Reported on February 24, 2022
Safe Harbor Statement © 2022 The Joint Corp. All Rights Reserved. 2 Certain statements contained in this presentation are "forward - looking statements” about future events and expectations. Forward - looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the in formation currently available to us. These statements are not statements of historical fact. Forward - looking statements involve risks and uncertainties that may cause our actual results to differ material ly from the expectations of future results we express or imply in any forward - looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differ enc es include, but are not limited to, the continuing impact of the COVID - 19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient de mand), our failure to develop or acquire company - owned or managed clinics as rapidly as we intend, our failure to profitably operate company - owned or managed clinics, our inability to identify a nd recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, short - selling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, our failure to remediate the current or future material weaknesses in our internal control over financial reporting , w hich could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence, and other factors described in our filings with the SEC, including in the sec tio n entitled “Risk Factors” in our Annual Report on Form 10 - K for the year ended December 31, 2021 to be filed with the SEC and subsequently - filed current and quarterly reports.. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near - term," "long - term," "projections," "assumptions," "projects," "guid ance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward - looking statements. We qualify any forward - looking stateme nts entirely by these cautionary factors. We assume no obligation to update or revise any forward - looking statements for any reason or to update the reasons actual results could differ materially from tho se anticipated in these forward - looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any fut ure trends or indications of future performance, unless expressed as such, and should only be viewed as historical data. Business Structure The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, D ist rict of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washi ngt on, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.
Advancing Growth Strategy © 2022 The Joint Corp. All Rights Reserved. 3 Forging the Chiropractic Dream Accelerating the Pace of Clinic Growth Harnessing the Power of Our Data
Record Operating Metrics © 2022 The Joint Corp. All Rights Reserved. 4 1 New patient survey completed February 2021. 1.4M unique patients treated in 2021 807K new patients in 2021 10.9M adjustments in 2021 27% of new patients were new to chiropractic 1 85% system - wide gross sales from monthly memberships in 2021 Up from 1.1 M in 2020 and 998k in 2019 ~218K patients had never been to a chiropractor before Compared to 584K in 2020 and 585K in 2019 Up from 8.3M in 2020 and 7.7M in 2019 Consistent with 85% in 2020 and up from 80% in 2019
2021: Strongest Year Ever 5 Preliminary Change from 2021 2020 Revenue $81.2M Up 38% Op. Income $6.0M Up 9% Net Income $7.2M $(6.0)M Adjusted EBITDA 2 $13.3M Up 46% Unrestricted cash $19.5 M at December 31, 2021, compared to $20.6M Dec. 31, 2020 © 2022 The Joint Corp. All Rights Reserved. 1 Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed. 2 Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix. 39 % Increase in sy stem - wide sales 2021 over 2020 29% In crease in comp sales 1 for all clinics >13 months in operation 2021 over 2020 23 % In crease in comp sales 1 for all clinics >48 months in operation 2021 over 2020
12 26 82 175 242 265 309 352 394 453 515 610 4 47 61 47 48 60 64 96 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 TOTAL CLINICS OPEN Franchise Company Owned/Managed 156 Franchise Licenses Sold in 2021 - Up 29% YoY 130 Clinics Opened in 2021 - Up 78% YoY © 2022 The Joint Corp. All Rights Reserved. 6 2020 2021 Franchise Licenses Sold 121 156 Total New Franchised Clinics Opened 70 110 Greenfield Clinics Opened 3 20 Franchised Clinics Acquired 1 12 Clinics in Development 253 283 370 399 442 513 312 246 579 706
81% sold by RDs in 2021 71% of clinics supported by 21 RDs at December 31, 2021 RDs cover 59% of Metropolitan Statistical Areas (MSAs) at December 31, 2021 37 99 126 121 156 Dec. 31, 2017 Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2020 Dec. 31, 2021 616 715 841 962 1118 Dec. 31, 2017 Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2020 Dec. 31, 2021 112 155 204 253 283 Dec. 31, 2017 Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2020 Dec. 31, 2021 156 Franchise Licenses Sold in 2021, Up 29% YoY © 2022 The Joint Corp. All Rights Reserved. 7 1 Of the 1,118 franchise licenses sold as of December 31, 2021, 283 are in active development, 706 are currently operating and the balance represents terminated/closed licenses. Gross Cumulative Franchise Licenses Sold 1 Franchise Licenses Sold Annually Clinics in Active Development 1
Marketing Driving Growth 8 © 2022 The Joint Corp. All Rights Reserved. Annual Promotions • “Back Friday” package sale - up 27% • “End - of - Year” membership sale - up 42% 2022 National Brand Campaign “Don’t Do Pain. Do You.” • Targeting Millennial consumers, touting the power of chiropractic care for living their best lives • Airing on national streaming platforms, regional television buys, and other media channels
Preparing to Leverage New IT Platform © 2022 The Joint Corp. All Rights Reserved. 9 Initiatives • Improvements to the user experience • Enhanced promotional capabilities • Advanced analytics • Marketing automation • Native mobile app • Elevated risk control measures
Q4 2021 Preliminary Financial Results 10 $ in M 1 Q4 2021 Q4 2020 Differences Revenue • Corporate clinics • Franchise fees $22.4 12.2 10.2 $17.0 9.2 7.8 $5.4 3.0 2.4 32% 33% 30% Cost of revenue 2.4 1.9 0.5 24% Sales and marketing 2.9 2.1 0.8 38% Depreciation and amortization 1.8 0.7 1.1 170% G&A 14.6 9.5 5.1 53% Operating Income 0.7 2.8 (2.1) (76)% Tax Expense/(Benefit) 0.4 (7.9) 8.3 105% Net Income 0.2 10.6 (10.4) (98)% Adj. EBITDA 2 2.7 3.7 (1.0) (26)% © 2022 The Joint Corp. All Rights Reserved. 1 Due to rounding, numbers may not add up precisely to the totals. 2 Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.
Year - ended Dec. 31, 2021 Preliminary Financial Results 11 $ in M 1 2021 2020 Differences Revenue • Corporate clinics • Franchise fees $81.2 44.8 36.4 $58.7 31.8 26.9 $22.5 13.0 9.5 38% 41% 35% Cost of revenue 8.5 6.5 2.0 31% Sales and marketing 11.4 7.8 3.6 46% Depreciation and amortization 6.1 2.7 3.4 123% G&A 49.1 36.2 12.9 36% Operating Income 6.0 5.5 0.5 9% Tax Expense/(Benefit) (1.2) (7.8) 6.5 (84%) Net Income/(Loss) 7.2 13.2 (6.0) (46)% Adj. EBITDA 2 13.3 9.1 4.2 46% 1 Due to rounding, numbers may not add up precisely to the totals. 2 Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix. © 2022 The Joint Corp. All Rights Reserved. Unrestricted cash $19.5 M at Dec. 31, 2021, compared to $20.6M at Dec. 31, 2020
Providing 2022 Guidance 12 $ in M 2021 Actual 2022 Low Guidance 2022 High Guidance Revenues $81.2 $102.0 $106.0 Adjusted EBITDA 1 $13.3 $15.0 $17.0 New Franchised Clinic Openings 110 110 130 New Company - owned/Managed Clinics 2 32 30 40 © 2022 The Joint Corp. All Rights Reserved. 1 Reconciliation of Adjusted EBITDA to GAAP earnings is included in the appendix. 2 Through a combination of both greenfields and buybacks.
Advancing Growth Strategy © 2022 The Joint Corp. All Rights Reserved. 13 Forging the Chiropractic Dream Accelerating the Pace of Clinic Growth Harnessing the Power of Our Data
Resilient Business Model Drives Long - term Growth 14 People will continue to seek more noninvasive, holistic ways to manage their pain. We’ll be there to treat them. System - wide Sales ($ in M) 70% CAGR 1 (2010 - 2020) The Joint Corp. 11 - yr. CAGR 67% 1 vs. Industry CAGR 5.4% 2* 1 For the period ended Dec. 31, 2021 | 2 June 2021 Kentley Insights Chiropractic Care Market Research Report © 2022 The Joint Corp. All Rights Reserved. $1.3 $2.8 $8.1 $22.3 $46.2 $70.1 $98.6 $126.9 $165.1 $220.3 $260.0 $361.1 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Non - GAAP Measure Definition 15 This presentation includes non - GAAP financial measures. System - wide sales include sales at all clinics, whether operated by the company or by fran chisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understandi ng the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financia l h ealth of the franchisee base. Comp sales include the sales from both company - owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performan ce, as management believes they provide a more transparent view of the Company’s underlying operating performance and operating trends than GAAP measures alone. Reconciliat ion s of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interes t, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition - related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, and stock - based compensation expenses. EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operat ion s, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company’s financial statements fil ed with the SEC. © 2022 The Joint Corp. All Rights Reserved.
Q4 2021 Preliminary Segment Results 16 2021 Q4 © 2022 The Joint Corp. All Rights Reserved. $ in 000s
Year - ended Dec. 31, 2021 Preliminary Segment Results 17 2021 © 2021 The Joint Corp. All Rights Reserved. $ in 000s
Preliminary GAAP – Non - GAAP Reconciliation 18 © 2022 The Joint Corp. All Rights Reserved. $ in 000s
Jake Singleton, CFO jake.singleton@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245 - 5960 https://www.facebook.com/thejointchiro @ thejointchiro https://twitter.com/thejointchiro @ thejointchiro https://www.youtube.com/thejointcorp @ thejointcorp Peter D. Holt, President and CEO peter.holt@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245 - 5960 Kirsten Chapman, LHA Investor Relations thejoint@lhai.com LHA Investor Relations | One Market Street, Spear Tower, Suite 3600, San Francisco, CA 94105 | (415) 433 - 3777 © 2022 The Joint Corp. All Rights Reserved. 19 The Joint Corp. Contact Information
^YWYHE>8J6G#0XEF08VCW1VR>:[51-EN)C@IV^#1L&G#!C([!9G@OA
M.432>+LQ[_$ :5P:!T*4P
MFC.3N<-J>(@';KE;AU!3R@-Q))_-'+XJ+=:_3"0-(S]RI
MM7;-;;X14727,OAM]P=%N>%:ME)9HVSY!)+AMS'= .V1H>8G%P);I(!Y
M^FW/YE4MVGAC:T5D,FMH/AO9AA '?&01C'11X;L8I6MK!41/C.J([N&.VZ5QGQ17R7)O"7"K(ZJZDATU<#Y*5O?_ N^
M>6>ZM#&Y\MDRFL;VQ7)@[][/:>$%L50!5B32Z NU.P>1"L[/P'#9[2Z6L+7U
M$GF+21Y6],Y/Q*Z+;>&*2Q1-KKI4R7&YEH#ZJ8@N?Z-'[(5+Q17Q^#,Y\9#6
M\L.QG/(
:\B<'%GJ8Y[D;Z";;FIXE!:-LK+456#C)5O%.';
MZE,9$.)9%V>29F82=DB.H;W3NH.ZY6EV5Z(VEP2FGNG'-&"FB /BJM463OL=
M:X$;)YISS4-KB GXG:MU>+*M%C X8 Z*-7T3
UN1O@S;>&;"BN /,[JZIZW&,'8KGE+68 W5U35X.GS+R90<6>G&2:-O#
M4.<\;X"MH)AHY[K&4EP! !PK2"L!ZHI$N-FG$H<,(P%505(VW"GQS!V-\JZ9
M5JAT-WY;)QD?F!W"2T@[A.@YY*459(BY8S]5)C;V41FZEPA:Q9E(E,&6EKMP
M575E&^%^J+9GHK%C2-^B;JZV*)I83DGLN_%FV=G)DQ;^BK,;2S27$ J/)2Z3
MJ:[Y8R5-EN$> '-:0B.>&48P6_ KK6JQRZ9@]-D2(<;SI/AM(<.KMB4\7O>S
M6X8[J0ZG:7!\9:3_ #D]'&79#@UP(W'):QG&73,90E'M%8T-DD&@D_P3SVAI
M (..9RHU?05-+^OH@7,YD<\)-!=(*O$,V63 Y)*L4:8Z\#((R<;X*8>/+Z?%
M2Y(2)"[<-.V>B@/:1(XNSH!YJ *C=N< @]T]'(1AV,CT40O#HP0[;.$JGD<2
M'1N&ENV_52*+,'1CS>8J1 <$M<1Z*"V3!U'&!R*D-?Y]1(.1E61!8Q..^<8
M4RFK9J=P=%*0/W2JF%^7<]LI[6,YWPI:OLIRGP;&COL+H_[8\CAU R"A96!Q
MC;L3NA9>FC999&S:3GFGXP[.Q3+&J3#S7+9T4.MR!NEA',+Q2B11Y)ITH;S*
M9(=E-BR4A-"1>A^2I)
M'$+P.7H0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0
M A"$ (0A "$(0 A"$ (0A "$(0 D3_R+_@EINHU"%Y;N0,@*F5ZIHYZZ?4
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M)O#N=5)&7";QI,AIZ,+R-^9&&/ SG&6$8TX.+N][J9(JL4T1#=$@PP,R3N&^/V564E%6R4F^$5M]J((0YTK]$<0P.Q_H5RC
MBWB2>H=X-,UY)V:"=A\5<7N6KEE8V5DI.,[#(RJVELTDM1X\[1C&P'1<&3+*
M;J)O'&H\LS=#89:MXGNE2V-IZ%:RVT]DM[1YC(X=<*SI.&V5)&(SCKJ5LVQ6
MFWL#ZL1G&^Y_@KX\,NVO^2D\B?!"I[Q%@-HJ;4>F5-D?6/B$M5,RDA&^7'<_
M =5!K>(H:1GAVRF:T]"6[E5,=/7WF;Q*Z4MC/35NMO4KVKDIMODM#Q V.7P;
M3&Y\O[4\O/Y#HET]'55K]=9*^4GS&Q6B5LTD+JN=KG/!FW:"[F=/4^I
MRMRV-L;0&C P .B]/#I*7/!QY=3N?!SVIX:H^&K#%% 6EL8#(XSGS._$GJ2
M>RH86Z'
>9-6C#'@=.S VNQ3
MU$K(RTN.5MJ;A\DTL#7
B4R;1QV:R3L.' \NR:-EFQG23\E
MV>2R1:L^\>^.:<@LL)]YNW4 )3(HX;)9)\Y\-R%W@V&%VX9@=-D)[R:1]/H0
MA=I0$(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@
M!"$( 0A" $(0@ J!63 OT$G2TY.#S/92YGAD9)Z+,U54X02U!&SSB,=7>OSY
M!